18.03.2020 – IGEA Pharma N.V.

IGEA Pharma support Italian COVID-19 battle

IGEA Pharma N.V. / Key word(s): Miscellaneous
IGEA Pharma support Italian COVID-19 battle

18-March-2020 / 20:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


IGEA Pharma support Italian COVID-19 battle

Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today
announced an explosion in the demand for dry aerosol devices in Italy as a
result of the COVID-19 outbreak so severely affecting this country.

IGEA operates in air and surfaces sanitization with aerosol technology-based
devices following the understandings on the acquisition of privately held
Medical Jet. Vincenzo Moccia, CEO of IGEA: "The proven action of our aerosol
solutions together with Rely+On Virkon(R) in reducing a broad spectrum of
viruses and bacteria is highly appreciated. We remain fully committed to
contribute in solving the problems of contamination of the air and the
surfaces in the environments with high infections and life-threatening

The demand for aerosol solutions in Italy increased by 20 times compared to
historic demand. As a result, IGEA and Medial Jet are enhancing the
production capacities.


About IGEA
IGEA Pharma focuses on health-tech and med-tech products and devices.
Health-tech products are exclusively preventative. IGEA commercializes an
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit
to measure non-bound copper in the blood and 'Alz1 Tab', a natural dietary
supplement designed to reduce blood heavy metals content) and expects to
launch a diabetes type II prevention set in 2020. Non-ceruloplasmin bound
copper is an expected Alzheimer's and diabetes type II associated biomarker.
Determining and regulating non-bound copper can contribute to reduce the
risk of Alzheimer's and diabetes type II. Med-tech products focuses on
selected solutions and specialities. IGEA operates in air and inanimate
environmental surface sanitization with aerosol technology-based devices and
expects to start commercializing polymeric based infusion and transfusion
solutions during 2020.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

Vincenzo Moccia, CEO Patrick Pozzorini, CFO
Phone: +31 23 568 94 94/+39 340 583 09 33 Phone: +31 23 568 94 94/+41 79 314
41 43
moccia@igeapharma.com pozzorini@igeapharma.com

This document constitutes neither an offer to buy nor to subscribe
securities and neither this document nor any part of it should form the
basis of any investment decision in IGEA.

The information contained in this press release has been carefully prepared.
However, IGEA bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. IGEA does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This publication may contain specific forward-looking statements and
assessments or intentions concerning IGEA and its business. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors which may result in a substantial divergence
between the actual results, financial situation, development or performance
of IGEA and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. IGEA assumes no responsibility to update
forward-looking statements or to adapt them to future events or
developments, except as may be required by law.


End of ad hoc announcement